Allokraft

Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4) in 2011 and the seminal initial efficacy disclosure on nivolumab (anti-PD1) in 2012 (Topalian et al NEJM), we can reflect on how I-O has literally changed the lives of tens of thousands of cancer patients and their families.

Returning to work following the pandemic presents an opportunity to think creatively about how to re-configure the workplace

Today marks an important milestone for HotSpot Therapeutics as we announce our Series B financing, but it also marks a […]

DNA encoded libraries (DEL) have received a lot of attention over the past few years. They’ve been hailed as “highly […]

The conventional approach to drug discovery shines a light on specific target proteins, using an arsenal of biochemical and virtual […]

I was excited to participate in Allison Johnson’s recent Biocentury article reflecting on the growing interest of industry in allostery and why […]

Advances in computational, biophysical and library technologies have driven the emergence of a new drug discovery paradigm with the power […]

The predictions around the impact of artificial intelligence (AI) have been broad reaching but it’s clear that not everyone is […]

What is a regulatory hotspot? A regulatory hotspot is a privileged allosteric site used by nature to regulate the function […]